Afatinib for the treatment of metastatic non-small cell lung cancer

Keyphrases

• Afatinib 100%
• Metastatic Non-small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor 50%
• Exon 21 50%
• L858R 50%
• Non-small Cell Lung Cancer (NSCLC) 33%
• Sensitizing mutations 33%
• Exon 19 Deletion 33%
• Diarrhea 16%
• Erlotinib 16%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 16%
• Gefitinib 16%
• U.S. Food 16%
• Non-small Cell Lung Cancer Patients 16%
• Rash 16%
• Nave 16%
• Point mutation 16%
• Progression-free Survival 16%
• In-frame Deletion 16%
• Stomatitis 16%
• Substitution mutation 16%
• First-line Regimen 16%
• Acne 16%
• Exon 18 16%
• Tyrosine Kinase Domain 16%
• Exon 19 16%
• LUX-Lung 16%
• G719X 16%
• L861Q 16%
• Cancer Growth 16%
• Mutant Epidermal Growth Factor Receptor 16%
• ErbB Inhibitor 16%
• First-generation TKI 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Afatinib 100%
• Epidermal Growth Factor Receptor 66%
• Clinical Study 16%
• Diarrhea 16%
• Protein Tyrosine Kinase 16%
• Gefitinib 16%
• Progression Free Survival 16%
• Rash 16%
• Stomatitis 16%
• Acne 16%
• Cancer Growth Factor 16%
• Disease 16%
• Erlotinib 16%